| Literature DB >> 34684365 |
Jennifer L LaBarre1,2, Emily Hirschfeld3, Tanu Soni4, Maureen Kachman4, Janis Wigginton4, William Duren4,5, Johanna Y Fleischman6, Alla Karnovsky5, Charles F Burant1,6, Joyce M Lee3,7.
Abstract
As the incidence of obesity and type 2 diabetes (T2D) is occurring at a younger age, studying adolescent nutrient metabolism can provide insights on the development of T2D. Metabolic challenges, including an oral glucose tolerance test (OGTT) can assess the effects of perturbations in nutrient metabolism. Here, we present alterations in the global metabolome in response to an OGTT, classifying the influence of obesity and insulin resistance (IR) in adolescents that arrived at the clinic fasted and in a random-fed state. Participants were recruited as lean (n = 55, aged 8-17 years, BMI percentile 5-85%) and overweight and obese (OVOB, n = 228, aged 8-17 years, BMI percentile ≥ 85%). Untargeted metabolomics profiled 246 annotated metabolites in plasma at t0 and t60 min during the OGTT. Our results suggest that obesity and IR influence the switch from fatty acid (FA) to glucose oxidation in response to the OGTT. Obesity was associated with a blunted decline of acylcarnitines and fatty acid oxidation intermediates. In females, metabolites from the Fasted and Random-Fed OGTT were associated with HOMA-IR, including diacylglycerols, leucine/isoleucine, acylcarnitines, and phosphocholines. Our results indicate that at an early age, obesity and IR may influence the metabolome dynamics in response to a glucose challenge.Entities:
Keywords: acylcarnitines; adolescents; fatty acids; glucose challenge; insulin resistance; metabolomics; obesity; oral glucose tolerance test
Mesh:
Substances:
Year: 2021 PMID: 34684365 PMCID: PMC8538092 DOI: 10.3390/nu13103365
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study Design. Overweight and obese (OVOB) and lean participants were recruited prior to the first visit (Fasted Visit), where an oral glucose tolerance test (OGTT) (75 g) was administered in the fasted state. The OVOB participants returned approximately a week later for an OGTT (50 g) in a random fed state (Random-Fed Visit). Blood samples were collected before and during the OGTT and used for glucose, insulin, and untargeted metabolomics assays. Mean age and range of ages reported (years).
Characteristics of study participants at the Fasted Visit, stratified by weight group. Significance denoted with unadjusted p-value < 0.05 (bolded).
|
|
|
|
|
|
|
| ||
|
| |||
| Male | 97 (43%) | 26 (47%) | 0.5254 |
| Female | 131 (57%) | 29 (53%) | |
| race | |||
| Asian/Pacific Islander | 4 (2%) | 4 (7%) | 0.1745 |
| African American/Black | 59 (26%) | 12 (22%) | |
| White | 135 (59%) | 32 (58%) | |
| more than one race | 19 (8%) | 6 (11%) | |
| did not wish to report | 11 (5%) | 1 (2%) | |
| ethnicity | |||
| Hispanic | 18 (8%) | 5 (9%) | 0.7707 |
| non-Hispanic | 210 (92%) | 50 (91%) | |
| abnormal 2-hr plasma glucose (≥140 mg/dL) | |||
| Yes | 16 (7%) | 3 (5%) | 0.6776 |
| No | 212 (93%) | 52 (95%) | |
| abnormal fasting plasma glucose (≥100 mg/dL) | |||
| Yes | 8 (4%) | 1 (2%) | 0.5213 |
| No | 220 (96%) | 54 (98%) | |
| ADA prediabetes (FPG≥ 100 mg/dL or 2-hr PG ≥ 140 mg/dL or HbA1c ≥ 5.7%) | |||
| Yes | 35 (15%) | 6 (12%) | 0.4009 |
| No | 193 (85%) | 49 (88%) | |
|
|
|
|
|
|
|
| ||
| age (years) | 12.9 (2.5) | 13.0 (2.6) | 0.7301 |
| BMI percentile | 95 (4) | 59 (27) |
|
| HOMA-IR | 5.13 (2.99) | 2.80 (1.21) 3 |
|
| HbA1c | 5.2 (0.3) | 5.1 (0.3) 3 | 0.2082 |
| fast time (hours) | 14.0 (1.3) | 14.1 (1.4) | 0.7606 |
| fasting OGTT response | |||
| glucose (t0) (mg/dL) | 84 (8) | 85 (8) | 0.7475 |
| glucose (t30) (mg/dL) | 126 (22) | 132 (25) | 0.1119 |
| glucose (t60) (mg/dL) | 112 (29) | 117 (26) | 0.2182 |
| glucose (t90) (mg/dL) | 107 (26) | 106 (21) | 0.6263 |
| glucose (t120) (mg/dL) | 102 (24) | 98 (22) | 0.2562 |
| insulin (t0) (µU/mL) | 24 (14) | 13 (5) 3 |
|
| insulin (t30) (µU/mL) | 194 (132) | 112 (72) |
|
| insulin (t60) (µU/mL) | 156 (117) | 87 (53) |
|
| insulin (t90) (µU/mL) | 145 (126) | 80 (56) |
|
| insulin (t120) (µU/mL) | 133 (117) | 65 (57) |
|
| AUC glucose | 3121 (2112) | 3294 (1711) | 0.5228 |
| AUC insulin | 17,223 (11,206) | 9648 (5468) |
|
1 Represents Pearson’s chi-square test for categorical variables. 2 Represents unpaired t-test for continuous variables. 3 n = 54.
Figure 2Kinetics of blood glucose and insulin response to the glucose test at the Fasted Visit. OVOB and lean participants arrived fasted prior to the consumption of the glucose challenge. Blood glucose and insulin were profiled before and during the OGTT. Mean values reported for lean (dark pink dash) and OVOB (dark slate gray dash). OVOB, overweight and obese.
Figure 3Differential metabolites between OVOB and lean participants during the Fasted OGTT Challenge. Linear regression analyses identified metabolites associated with the OVOB and lean groups at t0 (ßgroup), adjusting for sex and age (FDR < 0.1, 66 metabolites). Selected differential metabolites represent metabolic pathways associated with obesity at t0. Normalized peak intensities and standard deviations are reported.
Figure 4Dynamic response of the metabolome to an oral glucose tolerance test. Heatmap of normalized peak intensity for individual metabolites (p = 246) (mean 0, standard deviation 1). Metabolites are grouped by hierarchical clustering (columns). Subjects are ordered by group (OVOB and lean), time point after the OGTT (t0 and t60), and state (Fasted and Random-Fed) (rows). OVOB, overweight and obese.
Figure 5Differential metabolites between Fasted and Random-Fed in OVOB. Linear regression analyses identified metabolites associated with OVOB-Fasted and OVOB-Random-Fed (ßstate) at (A) t0 and (B) t60. On the top of the plots, metabolites are reported that are higher in OVOB-Fasted (ßstate < 0), with position indicated by −log10 (p-value). On the bottom of the plots, metabolites are reported that are lower in OVOB-Fasted (ßstate > 0), with position indicated by −log10 (p-value). Metabolites are listed in the same order in 5A and 5B. Colors indicate metabolite class. Horizontal lines (dotted) signify FDR = 0.1. Several distinguishing metabolite names are listed. Age and sex are included in the model.
Metabolites associated with HOMA-IR in females with overweight and obesity at the Fasted and Random-Fed Visit. Beta coefficients and standard errors from linear regression models are reported, adjusting for age at the Fasted Visit (FDR < 0.1).
| Metabolite | Pathway | Fasted t0 | Fasted t60 | Fasted Fold Change | Random-Fed t0 | Random-Fed t60 |
|---|---|---|---|---|---|---|
| AC 12:0 | acylcarnitine | 2.0 ± 0.3 | ||||
| AC 12:1 | acylcarnitine | 2.7 ± 0.5 | ||||
| AC 14:0 | acylcarnitine | 2.3 ± 0.8 | ||||
| AC 16:0 | acylcarnitine | 2.6 ± 0.6 | ||||
| AC 16:1 | acylcarnitine | 1.3 ± 0.7 | ||||
| AC 18:0 | acylcarnitine | 1.6 ± 0.2 | ||||
| AC 5:0-OH | acylcarnitine | 0.9 ± 0.3 | ||||
| AC 5:1 | acylcarnitine | 1.5 ± 1.6 | ||||
| AC 6:0 | acylcarnitine | 1.7 ± 0.6 | ||||
| gamma-glutamyltyrosine | amino acid | 0.8 ± 0.2 | 0.9 ± 0.3 | 0.9 ± 0.3 | ||
| Glu-Phe | amino acid | 0.9 ± 0.2 | ||||
| glutamate | amino acid | 0.7 ± 0.3 | 0.9 ± 0.3 | |||
| indole-3-methyl acetate | amino acid | 0.7 ± 0.3 | ||||
| L-gamma-glutamylisoleucine | amino acid | 0.8 ± 0.3 | ||||
| Leu-Ile | amino acid | 0.7 ± 0.5 | 0.9 ± 0.2 | |||
| leucine+isoleucine | amino acid | 0.7 ± 0.3 | ||||
| N-acetylphenylalanine | amino acid | 0.7 ± 0.3 | ||||
| Phe-Phe | amino acid | −0.7 ± 0.3 | ||||
| Phe-Trp | amino acid | 0.7 ± 0.3 | ||||
| pipecolate | amino acid | −0.6 ± 1.1 | ||||
| proline | amino acid | 0.7 ± 0.3 | ||||
| cholate | bile acid | 0.8 ± 0.3 | ||||
| hyocholate | bile acid | 0.8 ± 0.3 | ||||
| indole-3-lactate | carbohydrate | 0.7 ± 0.3 | ||||
| caffeine | exogenous | 1.7 ± 0.6 | ||||
| FA 18:4 | fatty acid | 0.8 ± 0.3 | ||||
| FA 20:3 | fatty acid | 1.1 ± 0.3 | ||||
| FA 22:1 | fatty acid | 1.9 ± 0.5 | ||||
| 3-hydroxyphenyl-valerate | fatty acid intermediate | 0.9 ± 0.6 | ||||
| DG 32:0 | lipid | 1.2 ± 0.2 | 1.2 ± 0.2 | 2.2 ± 0.4 | 1.1 ± 0.2 | 1.0 ± 0.2 |
| DG 32:1 | lipid | 1.0 ± 0.2 | 1.1 ± 0.2 | 0.9 ± 0.2 | 0.8 ± 0.2 | |
| DG 34:1 | lipid | 1.0 ± 0.2 | 0.9 ± 0.2 | 0.9 ± 0.2 | ||
| DG 34:2 | lipid | 1.1 ± 0.2 | 1.0 ± 0.2 | 0.9 ± 0.2 | 0.8 ± 0.2 | |
| DG 36:2 | lipid | 0.7 ± 0.2 | ||||
| DG 36:3 | lipid | 0.7 ± 0.3 | ||||
| MG 14:0 | lipid | 1.0 ± 0.2 | ||||
| MG 16:0 | lipid | 1.2 ± 0.3 | ||||
| MG 18:1 | lipid | 0.8 ± 0.2 | 0.9 ± 0.2 | 0.7 ± 0.3 | ||
| LPC 16:0 | lipid | 1.1 ± 1.2 | ||||
| LPC 18:2 | lipid | 0.8 ± 1.7 | ||||
| PC 32:1 | lipid | 0.8 ± 0.2 | 1.0 ± 0.4 | |||
| PC 34:3 | lipid | 0.7 ± 0.3 | ||||
| PC 34:4 | lipid | 0.7 ± 0.3 | ||||
| N2,N2-dimethylguanosine | nucleotide | 0.7 ± 0.3 | ||||
| urate | nucleotide | 0.8 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.9 ± 0.2 |